N-[(2R)-1-(6-aminohexylamino)-1-oxo-3-sulfanylpropan-2-yl]-2,2-dimethyl-3-sulfanylpropanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[(2R)-1-(6-aminohexylamino)-1-oxo-3-sulfanylpropan-2-yl]-2,2-dimethyl-3-sulfanylpropanamide
• 化学式: C₁₄H₂₉N₃O₂S₂
• 分子量: 335.5
• InChiKey: JMQBOXIMQGQUAG-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  21
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  86.2
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• AMINO ACID DERIVATIVE
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP0455833A1

  公开（公告）日：1991-11-13

  A novel compound of general formula (I), which is useful for treating diseases caused by various immune disorders such as immunodeficiency or autoimmune disease, a process for producing the same, and a pharmaceutical composition containing the same as an active ingredient.

  一种新型通式(I)化合物，可用于治疗由各种免疫失调（如免疫缺陷或自身免疫疾病）引起的疾病；一种生产该化合物的工艺；以及一种含有该化合物作为活性成分的药物组合物。
• ANGIOGENESIS INHIBITOR
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP1142570A1

  公开（公告）日：2001-10-10

  An object of the present invention is to find new pharmacological effects of cysteine derivatives. Studying new pharmacological effects of the cysteine derivatives, the cysteine derivatives were found to exhibit excellent effects of inhibiting angiogenesis. Accordingly, these cysteine derivatives are expected to be useful as therapeutic agents for diseases in which the angiogenesis participates, particularly retinal diseases such as diabetic retinopathy, macular degeneration, retinal vein occlusion and retinal artery occlusion, neovascular glaucoma and tumors such as hemangioma.

  本发明的目的是寻找半胱氨酸衍生物的新药理作用。在研究半胱氨酸衍生物的新药理作用时，发现这些半胱氨酸衍生物具有极佳的抑制血管生成的效果。因此，这些半胱氨酸衍生物有望作为治疗剂用于治疗血管生成参与的疾病，特别是视网膜疾病，如糖尿病视网膜病变、黄斑变性、视网膜静脉闭塞和视网膜动脉闭塞、新生血管性青光眼和肿瘤，如血管瘤。
• Angiogenesis inhibitors
  申请人：——

  公开号：US20010041744A1

  公开（公告）日：2001-11-15

  A method for inhibiting angiogenesis comprising administering to a patient (mammal, such as a human) in need thereof, a pharmaceutically effective amount of an angiogenesis inhibitor containing a compound of formula (I) or a pharmaceutically acceptable salt thereof, either alone or in combination with a pharmaceutically acceptable carrier. The method of treatment may be used to treat diseases in which the angiogenesis participates, particularly retinal diseases such as diabetic retinopathy, macular degeneration, retinal vein occlusion and retinal artery occlusion, neovascular glaucoma and tumors such as hemangioma. Formula (I): 1

  一种抑制血管生成的方法，包括向有需要的患者（哺乳动物，如人）单独或与药学上可接受的载体结合施用药学上有效量的含有式（I）化合物或其药学上可接受的盐的血管生成抑制剂。该治疗方法可用于治疗血管生成参与的疾病，特别是视网膜疾病，如糖尿病视网膜病变、黄斑变性、视网膜静脉闭塞和视网膜动脉闭塞、新生血管性青光眼和肿瘤，如血管瘤。 式（I）： 1
• JP2000169388A
  申请人：——

  公开号：JP2000169388A

  公开（公告）日：2000-06-20
• US6444705B2
  申请人：——

  公开号：US6444705B2

  公开（公告）日：2002-09-03